MoonLake Immunotherapeutics (NASDAQ: MLTX) is -19.10% lower on its value in year-to-date trading and has touched a low of $37.55 and a high of $64.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MLTX stock was last observed hovering at around $41.47 in the last trading session, with the day’s gains setting it 2.34%.
Currently trading at $43.81, the stock is -12.60% and -14.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 5.64% at the moment leaves the stock -6.43% off its SMA200. MLTX registered -22.34% loss for a year compared to 6-month gain of -2.69%. The firm has a 50-day simple moving average (SMA 50) of $51.4794 and a 200-day simple moving average (SMA200) of $46.82025.
The stock witnessed a -17.31% loss in the last 1 month and extending the period to 3 months gives it a -10.81%, and is -5.41% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.29% over the week and 6.32% over the month.
MoonLake Immunotherapeutics (MLTX) has around 50 employees, a market worth around $2.80B and $0.00M in sales. Distance from 52-week low is 16.67% and -32.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.48%).
The EPS is expected to shrink by -144.90% this year.
MoonLake Immunotherapeutics (MLTX) Top Institutional Holders
175.0 institutions hold shares in MoonLake Immunotherapeutics (MLTX), with institutional investors hold 115.76% of the company’s shares. The shares outstanding are 63.05M, and float is at 52.84M with Short Float at 15.29%. Institutions hold 98.13% of the Float.
The top institutional shareholder in the company is BVF INC/IL with over 21.75 million shares valued at $956.4 million. The investor’s holdings represent 34.7258% of the MLTX Shares outstanding. As of 2024-06-30, the second largest holder is CORMORANT ASSET MANAGEMENT, LP with 8.49 million shares valued at $373.49 million to account for 13.5609 of the shares outstanding. The other top investors are FMR LLC which holds 3.64 million shares representing 5.8176% and valued at over $160.23 million, while AVORO CAPITAL ADVISORS LLC holds 4.4223 of the shares totaling 2.77 million with a market value of $121.8 million.
MoonLake Immunotherapeutics (MLTX) Insider Activity
The most recent transaction is an insider sale by BVF PARTNERS L P/IL, the company’s Director. SEC filings show that BVF PARTNERS L P/IL sold 2,000,000 shares of the company’s common stock on Oct 04 ’24 at a price of $50.00 per share for a total of $100.0 million. Following the sale, the insider now owns 1.29 million shares.
MoonLake Immunotherapeutics disclosed in a document filed with the SEC on Oct 04 ’24 that Sturge Simon (Director) sold a total of 171,000 shares of the company’s common stock. The trade occurred on Oct 04 ’24 and was made at $53.72 per share for $9.19 million. Following the transaction, the insider now directly holds 0.17 million shares of the MLTX stock.
Still, SEC filings show that on Feb 27 ’24, Santos da Silva Jorge (Chief Executive Officer) disposed off 62,810 shares at an average price of $55.00 for $3.45 million. The insider now directly holds 3,043,619 shares of MoonLake Immunotherapeutics (MLTX).
